Cabaletta Bio (CABA) announced new and updated clinical data on CABA-201 demonstrating the potential to achieve drug-free, compelling clinical responses based on eight patients dosed across the ...

As of the end of Q1 2025, CABA held $131.8 million in cash and equivalents. They incurred $37.1 million in operating expenses, $29 million of which came from research and development.

Initial Phase 1 of 2 RESET-Myositis and RESET-SLE clinical trial data of the investigational therapy, CABA-201, revealed positive outcomes. The first two study participants did not exhibit infections ...

CABA-201, an investigational therapy by Cabaletta Bio, Inc. has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) as a possible treatment for lupus and lupus nephritis ...